Opdivo Poised to Become a Treatment for Gastric Cancer
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- February 3, 2017
- Reading time: 1 minute
In response to patient inquiries about recent cancer medication news, we have translated the ASCO 2017 report on Nivolumab (Opdivo), an anti-PD-1 antibody. This report discusses its use for unresectable or recurrent gastric cancer patients who are ineligible for conventional treatments, showing it can reduce the mortality rate by 37%. The final analysis of the double-blind, randomized Phase III clinical trial ONO-4538-12 was published. The results showed a significant improvement in overall survival (OS) in the Opdivo group compared to the placebo group, proving that this drug can become a viable third-line treatment option. The results were presented by Yoon-Koo Kang from the University of Ulsan College of Medicine, South Korea, at the Gastrointestinal Cancers Symposium held in San Francisco from January 19 to 21.
The ONO-4538-12 trial targeted patients with recurrent gastric cancer who were ineligible for standard therapy (Nivolumab 3mg/kg administered every two weeks) versus a placebo. This study involved 49 medical facilities across Japan, South Korea, and Taiwan. From November 2014 to February 2016, a total of 493 participants were enrolled: 330 in the Nivolumab group and 163 in the placebo group. Data collection concluded in August 2016. The patient characteristics were as follows: In the Nivolumab group, the median age was 62 (20–83), 57.3% were under 65, 69.4% were male, 46.1% were Japanese, 74.5% had metastasis in two or more organs, 20.9% had received two prior lines of therapy, 41.5% had three, and 37.6% had four or more. Prior treatments included 5-FU (99.7%), platinum-based drugs (94.2%), paclitaxel (86.1%), irinotecan (74.8%), and ramucirumab (10.6%).
In the placebo group, the median age was 61 (26–83), 58.3% were under 65, 73.0% were male, 73.0% had metastasis in two or more organs, 17.8% had received two lines of therapy, 38.0% had three, and 44.2% had four or more. Prior treatments included 5-FU (100%), platinum-based drugs (96.3%), paclitaxel (85.9%), irinotecan (75.5%), and ramucirumab (13.5%).
The median overall survival (OS) for the Nivolumab group was 5.32 months (95% CI: 4.63–6.41), compared to 4.14 months for the placebo group (95% CI: 3.42–4.86), p < 0.0001, indicating significantly better outcomes for the Nivolumab group. The 12-month OS rate was 26.6% for the Nivolumab group (95% CI: 21.1–32.4) and 10.9% for the placebo group (95% CI: 6.2–17.0). The 6-month OS was 46.4% for the Nivolumab group and 34.7% for the placebo group.
Clinical trial link: https://clinicaltrials.gov/show/NCT02267343
Source: Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. (Abstract No. 2)
Gastric Cancer
- Immunotherapy
- (Solid Tumors) Is Keytruda Effective?
- (Solid Tumors) Rakuten Medical Initiates Phase I Clinical Trial for RM-1995 Photo-immunotherapy
- (Lung Cancer) Is Keytruda Effective?
Medical Supporter Formerly certified by Japan's Ministry of Foreign Affairs and METI as an international medical visa guarantor (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4